History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Yankees Universe Fund Fred's Team Cycle for Survival Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment
We're Ready To Help
We're Ready To Help
Call us to schedule an appointment or contact us online

Memorial Sloan-Kettering physicians make treatment recommendations for kidney tumors based on the specific tumor size, location, and stage of the disease -- that is, how large the tumor has grown, how deeply it has invaded the kidney, and whether it has spread to nearby organs, lymph nodes, or another part of the body. Treatment may include surgery, chemotherapy, radiation therapy, or immunological therapy, alone or in combination. Our doctors have expertise in the management of both localized and advanced kidney tumors.

Surgery

Renal Cell Carcinoma Nomogram
Renal Cell Carcinoma Nomogram
Our nomogram helps physicians and patients decide which treatment approaches will result in the greatest benefit

Surgery is the most common form of treatment for kidney tumors, and it is often the only treatment necessary. Memorial Sloan-Kettering's urologic surgeons have expertise in all surgical approaches to kidney tumors, including kidney-sparing and laparoscopic surgery.

If an operation is necessary, our team of specialists will evaluate the patient and, based on the size and location of the tumor, recommend either removal of the tumor (partial nephrectomy) or removal of the entire tumor-bearing kidney (complete, or radical, nephrectomy).

Partial Nephrectomy: Kidney-Sparing Surgery

Kidney-sparing (or nephron-sparing) surgery is the term used to describe the procedure in which a kidney tumor is removed, leaving a margin of normal kidney tissue in order to preserve the function of the remaining kidney. Studies conducted at Memorial Sloan-Kettering and other institutions have demonstrated that partial nephrectomy yields comparable results to complete nephrectomy in patients with small tumors (less than 4 centimeters), while maintaining functioning kidney tissue. Our surgeons are experienced in performing these technically demanding operations. In appropriate situations, our team can offer laparoscopic partial nephrectomy. In 2007, our surgeons performed 223 partial nephrectomy procedures, 57 of which were done laparoscopically.

Complete (Radical) Nephrectomy

In some situations, the entire kidney needs to be removed. Tumors that require complete nephrectomy tend to be larger in size and to have advanced locally, though sometimes they have spread to another part of the body. Our team can help determine whether patients with such tumors may be best served by laparoscopic or open nephrectomy. Because we are able to offer all possible modes of treatment, we can tailor the approach to each individual patient.

For transitional cell carcinoma of the kidneys and ureters, surgical approaches include removing the kidney and ureter (nephroureterectomy) and partially removing the ureter (segmental resection). These procedures can also be performed laparoscopically. When transitional cell carcinoma is found on the surface of the renal pelvis or ureter, it may be treated by laser surgery, which uses a narrow beam of light to remove cancer cells.

During the surgery, the doctor may remove nearby lymph nodes to examine them for cancer cells. Pathologists will examine the cells of the tumor to determine which type of cancer is present.

Systemic (Whole-Body) Therapy

Find a Clinical Trial
Find a Clinical Trial
Find out about new research studies for kidney cancer

Conventional, or clear cell, renal cancer does not respond to traditional chemotherapy, but does respond to immunotherapy or drugs referred to as "targeted therapies" (also known as signal transduction inhibitors). In contrast, transitional cell carcinoma is sensitive to chemotherapy and is used to treat patients with advanced cancer of this type. More information on treating transitional cell carcinoma can be found on our Web site in the section on bladder cancer.

Targeted therapies take advantage of recent information about how conventional clear cell kidney cancer develops. For clear cell kidney cancer, clinical studies have compared several targeted therapies (sunitinib, temsirolimus, and sorafenib) to interferon and have shown that these drugs are as good as or better than interferon. For non-clear cell subtypes, less is known about the effectiveness of such therapies.

For kidney tumors that have spread widely to other parts of the body, Memorial Sloan-Kettering's medical oncologists have access to the latest systemic therapies available. Two older drugs that stimulate the immune system -- interleukin 2 (IL-2) and interferon -- have shown promise in treating some renal cancers. Antibodies that target molecules on the outside of kidney cancer cells are also being studied.

Sidney Kimmel Center for Prostate & Urologic Cancers
Sidney Kimmel Center for Prostate & Urologic Cancers
Our state-of-the-art
outpatient
facility offers
comprehensive care

Investigational approaches are sometimes offered to eligible patients through the clinical trial process.

Radiation Therapy

Radiation therapy is sometimes given as the primary form of treatment for patients who are not well enough to undergo surgery, although kidney tumors are often less sensitive to radiation. It can also be used to relieve symptoms of kidney cancer, such as pain, bleeding, or problems caused by the original cancer spreading to other parts of the body.


Last Updated: Apr. 21, 2008
PrintEmail This Page